Search

everythinglearnresearchcommunity

for

Search:↓

Ipilimumab can cause various adverse events in elderly patients, especially affecting the gastrointestinal and endocrine systems.

Over 30 potential cancer prevention treatments are being tested, with some showing promise in early research.

JAK inhibitors can enter the skin through hair follicles using a unique pathway.

The treatment significantly improved lymphocytic cicatricial alopecia symptoms in most patients.

RC48 shows promise for treating certain advanced cancers, but more research is needed.

Ritlecitinib works well and is safe for treating alopecia areata.

Upadacitinib effectively treats psoriasis and lichen planus together.

Keratinocyte growth factor promotes hair growth and reduces hair loss from chemotherapy.

Disrupting the Flcn gene in mice causes early kidney cysts and tumors, which can be treated with rapamycin.

Baricitinib works better than methotrexate for severe alopecia areata.

Fzd2 is important for skin and hair development through various signaling ways.

A man's severe skin reaction from cancer treatment improved with early diagnosis and proper medication.

Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.

Blocking a certain signal in the gp130 receptor can improve tissue healing and lessen osteoarthritis symptoms.

Continued ritlecitinib treatment can improve hair regrowth in some alopecia areata patients who initially don't respond.

PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.

Cancer treatment drugs can cause permanent hair loss by damaging hair follicle stem cells, but a specific inhibitor might reverse this effect.

Blocking EGFR can cause skin inflammation by disrupting IL-1 signaling.

The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.

VYN201 shows promise as a safe and effective treatment for non-segmental vitiligo.

JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.

Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.

The folate-cyclodextrin conjugate targets cancer cells more precisely, potentially reducing chemotherapy side effects.

JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.

Presurgical models can effectively and affordably screen cancer prevention agents.

PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.

Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.

Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.

Ritlecitinib is generally safe for alopecia areata patients over 72 months.

Ritlecitinib is an effective new treatment for Alopecia Areata.